Disseminated Gonococcal Arthritis: Antibiotic Choice Amid Rising Resistance
A young man develops fever, tenosynovitis, and a pustular rash from disseminated gonococcal infection, with a specific travel-linked exposure raising a resistance concern the average-population guideline wasn't written to anticipate. The disagreement is whether to add empiric azithromycin against current guidance, or to hold the line on ceftriaxone monotherapy and let culture data decide.
Devon L., a 27-year-old man, has spent the last four months training for his first triathlon, six mornings a week before work, and had planned to swim two miles this morning before the fever and the swollen, painful wrist stopped him at the door. Over the past three days he's developed migratory joint pain, tenderness along the tendons of his right wrist and left ankle, and a handful of small pustular lesions on his fingers and forearms. He is otherwise healthy, with no prior significant medical history, and reports a new sexual partner within the past month, with inconsistent condom use — a detail he volunteered without being asked once the differential came up.
Nucleic acid amplification testing of a urethral swab came back positive for Neisseria gonorrhoeae, and his presentation — fever, tenosynovitis, and pustular skin lesions without a single dominant purulent joint — fits the arthritis-dermatitis syndrome of disseminated gonococcal infection rather than the less common frankly septic monoarticular form. A knee aspirate obtained given a small effusion was sterile on Gram stain, consistent with that pattern: this syndrome is thought to reflect a bacteremic, immune-complex process rather than direct joint invasion, which is exactly why a sterile tap doesn't argue against the diagnosis the way it would in a monoarticular presentation. NAAT confirms the organism is present, but it says nothing about how susceptible it is; that answer depends on the culture sent in parallel, which will take another day or two to result. One detail is doing real work in how the team is weighing the interim plan: his new partner recently returned from several weeks of travel through a region with reported clusters of reduced-susceptibility Neisseria gonorrhoeae, a specific, named exposure the 2021 CDC guideline's population-level dosing recommendation was never written to individually account for.
Emergency department, admission for IV therapy
Ceftriaxone one gram IV every twenty-four hours, plus doxycycline one hundred milligrams twice daily for seven days — his chlamydia co-test is still pending, and the 2021 CDC guideline pairs an antichlamydial agent with the ceftriaxone whenever chlamydia hasn't been excluded. What I would not add is azithromycin. The same guideline dropped routine dual therapy specifically because adding a macrolide doesn't improve cure rates against the current U.S. gonococcal population and does add resistance pressure we don't need to create. Step down to oral cefixime once he's clinically improving, to complete at least seven days total.
I'd agree with you for the average patient walking through that door, and I'm not arguing the 2021 guideline is wrong on the population data it's built from. But his partner just returned from a region where CDC's own more recent alerts have flagged clusters of reduced-susceptibility Neisseria gonorrhoeae, including strains with reduced ceftriaxone susceptibility. That's not a hypothetical risk factor, it's the specific exposure pattern those alerts exist to flag.
The guideline you're citing describes what works against the average U.S. isolate. It was never written to answer whether an individual patient with a documented, matching exposure history should be managed identically to someone with no such history. I'd add azithromycin empirically and hold off on any step-down until culture susceptibility comes back, even knowing that deviates from the standard regimen.
And before you say it — I know exactly what I'm reaching for. Azithromycin is not a good answer to a ceftriaxone question. GISP had nearly five percent of isolates sitting at an elevated azithromycin minimum inhibitory concentration by 2018, which is half the reason dual therapy was dropped at all. He is also about to be on doxycycline for the pending chlamydia co-test, so a macrolide on top is a third overlapping agent against an organism it may well not cover either. I would still give the single dose, and I would give it knowing it buys less than I want it to, because the alternative is adding nothing at all for forty-eight hours in exactly the exposure history CDC's alerts exist to flag.
Whatever you two land on for the antibiotic itself, I'd separately push back on early oral conversion regardless. The step-down data behind the guideline's seven-day recommendation is thinner for exactly his presentation — bacteremic, multi-site, arthritis-dermatitis syndrome — than it is for uncomplicated mucosal gonorrhea, which is most of what that evidence base is built from. I'd keep him on IV therapy longer than the minimum either of you is debating, independent of which drug is running through it.
Agreed: start ceftriaxone with guideline-directed doxycycline cotreatment for as-yet-unexcluded chlamydia, plus a single empiric dose of azithromycin given the documented travel-linked exposure pattern, while awaiting culture and susceptibility data; do not convert to oral cefixime at the usual twenty-four-to-forty-eight-hour improvement mark, and instead plan a longer minimum course of IV therapy given the arthritis-dermatitis phenotype's thinner step-down evidence base.
The decision to add azithromycin was treated explicitly as a deviation from the current guideline, tied to this patient's specific exposure history rather than a broader change in how the team manages gonococcal infection generally — to be revisited the moment culture susceptibility results are available, whichever way they come back.